Newly Diagnosed T- Lymphoblastic Leukemia

Status: open

[824258-5] Protocol AALL1231 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

Treatment for Pediatric Oncology - T Acute Lymphoblastic Leukemia

Contact Us Or call 251-405-5121

Description

This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma. Bortezomib may help reduce the number of leukemia or lymphoma cells by blocking some of the enzymes needed for cell growth. It may also help chemotherapy work better by making cancer cells more sensitive to the drugs. It is not yet known if giving standard chemotherapy with or without bortezomib is more effective in treating T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. IRB Number 15-260

Sponsors

This trial is sponsored by Children's Oncology Group.

Providers Associated With This Trial

Principle Investigator

This link will open in a new tab or window.